Anavex Life Sciences Corp (AVXL)

[Investor2014]

Just except no news on the partnering they need for P3 to happen...

Neuren's Deal With FDA Reduces Uncertainty -- Market Talk
18:05 [Dow Jones] Neuren Pharmaceuticals's (NEU.AU) agreement with U.S. regulators on the design of a Phase 3 trial of its trofinetide treatment for Rett Syndrome makes the stock a less risky bet, says Bell Potter. The broker lifts its price target by 31% to A$0.17/share, and expects Neuren's partnering talks will now accelerate. "Subject to a partnering deal for trofinetide concluding in 1Q 2018, we expect that a Phase 3 trial for Rett could start in 2H 2018," says Bell Potter, which retains a buy call on the stock. ([e-mail]; @dwinningWSJ)


(END) Dow Jones Newswires

October 17, 2017 18:05 ET (22:05 GMT)